Fatalities associated with therapeutic use and overdose of atypical antipsychotics.

Abstract:

:Since 1989, several novel antipsychotic drugs have become available for use including clozapine, risperidone, olanzapine, quetiapine and ziprasidone. These agents represent a substantial improvement in the treatment of schizophrenia and related disorders and are considered to have a favourable adverse effect profile relative to traditional antipsychotics. Nonetheless, in rare cases, people have died as a result of taking atypical antipsychotic drugs at therapeutic and supratherapeutic doses. Toxic doses of atypical antipsychotics are highly variable: some patients have died while taking therapeutic doses and others have survived massive overdoses. Toxicity may be increased by coingestion of other agents, particularly drugs with similar metabolic pathways. Atypical antipsychotics are metabolised predominantly by cytochrome p450 (CYP) isoenzymes, particularly CYP1A2 (clozapine and olanzapine), CYP3A4 (clozapine, quetiapine and ziprasidone) and CYP2D6 (olanzapine and risperidone). Concurrent prescription of other drugs that inhibit these isoenzymes may increase the probability of adverse events in patients taking atypical antipsychotics. Deaths due to atypical antipsychotic toxicity are often related to cardiovascular complications, but pulmonary, neurological, endocrine and gastrointestinal complications have also caused fatalities. Prevention and management of atypical antipsychotic overdose are of increased clinical relevance as prescription of these drugs increases.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Trenton A,Currier G,Zwemer F

doi

10.2165/00023210-200317050-00002

subject

Has Abstract

pub_date

2003-01-01 00:00:00

pages

307-24

issue

5

eissn

1172-7047

issn

1179-1934

pii

1752

journal_volume

17

pub_type

杂志文章,评审
  • Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

    abstract::L-Dopa-induced dyskinesias (LID) are the most common adverse effects of long-term dopaminergic therapy in Parkinson's disease (PD). However, the exact mechanisms underlying dyskinesia are still unclear. For a long time, nigrostriatal degeneration and pulsatile stimulation of striatal postsynaptic receptors have been h...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-014-0205-z

    authors: Schaeffer E,Pilotto A,Berg D

    更新日期:2014-12-01 00:00:00

  • Therapeutic options for treatment-resistant depression.

    abstract::Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health's (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the fai...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11530280-000000000-00000

    authors: Shelton RC,Osuntokun O,Heinloth AN,Corya SA

    更新日期:2010-02-01 00:00:00

  • The glutamatergic system and Alzheimer's disease: therapeutic implications.

    abstract::Alzheimer's disease affects nearly 5 million Americans currently and, as a result of the baby boomer cohort, is predicted to affect 14 million Americans and 22 million persons totally worldwide in just a few decades. Alzheimer's disease is present in nearly half of individuals aged 85 years. The main symptom of Alzhei...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317090-00004

    authors: Butterfield DA,Pocernich CB

    更新日期:2003-01-01 00:00:00

  • Hashimoto's encephalopathy : epidemiology, pathogenesis and management.

    abstract::Hashimoto's encephalopathy is a term used to describe an encephalopathy of presumed autoimmune origin characterised by high titres of antithyroid peroxidase antibodies. In a similar fashion to autoimmune thyroid disease, Hashimoto's encephalopathy is more common in women than in men. It has been reported in paediatric...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200721100-00002

    authors: Mocellin R,Walterfang M,Velakoulis D

    更新日期:2007-01-01 00:00:00

  • Social anxiety disorder : current treatment recommendations.

    abstract::Social anxiety disorder (SAD) is a prevalent and disabling disorder associated with significant co-morbidity. An increased awareness of SAD over the past two decades has given impetus to advances in the pharmacotherapeutic and psychotherapeutic treatment options for this disorder. On the basis of consistent data from ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519050-00002

    authors: Muller JE,Koen L,Seedat S,Stein DJ

    更新日期:2005-01-01 00:00:00

  • New formulations of existing antidepressants: advantages in the management of depression.

    abstract::For nearly 50 years, antidepressant drugs have been the first-line treatment for various forms of depression. Despite their widespread use, these medications have significant shortcomings, in particular problems of patient compliance due to adverse effects. The introduction of new formulations of existing antidepressa...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418080-00003

    authors: Norman TR,Olver JS

    更新日期:2004-01-01 00:00:00

  • Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.

    abstract::Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first cli...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0299-y

    authors: Chan A,de Seze J,Comabella M

    更新日期:2016-01-01 00:00:00

  • VMAT2 Inhibitors in Neuropsychiatric Disorders.

    abstract::The basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders. Vesicular monoamine transporter 2 (VMAT2) inhibitors, which deplete dopamine at presynaptic striatal nerve terminals, are a class of drugs that have long been used to treat hyperkinetic movement disorders, but have rece...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0580-y

    authors: Tarakad A,Jimenez-Shahed J

    更新日期:2018-12-01 00:00:00

  • Topiramate: as monotherapy in newly diagnosed epilepsy.

    abstract::Topiramate is an antiepileptic drug that has a broad spectrum of antiseizure effects, which appear to be the result of several neurostabilising pharmacological mechanisms. These include blockade of ion channels, potentiation of GABA neuroinhibition and glutamate receptor antagonism at non-NMDA receptors, as well as mi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317130-00007

    authors: Waugh J,Goa KL

    更新日期:2003-01-01 00:00:00

  • Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.

    abstract::Despite the established efficacy of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies, translating CAR T therapy to solid tumors has remained investigational. Glioblastoma, the most aggressive and lethal form of primary brain tumor, has recently been among the malignancies being trialed clinic...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00687-3

    authors: Salinas RD,Durgin JS,O'Rourke DM

    更新日期:2020-02-01 00:00:00

  • The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review.

    abstract::The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of sa...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0517-5

    authors: Damkier P,Videbech P

    更新日期:2018-04-01 00:00:00

  • Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion.

    abstract:INTRODUCTION:Valproic acid is a versatile antiepileptic drug that is often used in the acute care setting. Intravenous valproic acid lends itself well to a continuous infusion as it exhibits a relatively short half-life. We evaluated the pharmacokinetics and clinical efficacy of continuous infusion valproic acid in hos...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0304-5

    authors: Cook AM,Zafar MS,Mathias S,Stewart AM,Albuja AC,Bensalem-Owen M,Kapoor S,Baumann RJ

    更新日期:2016-01-01 00:00:00

  • Diclofenac potassium powder for oral solution: a review of its use in patients with acute migraine.

    abstract::Diclofenac potassium powder for oral solution (Voltfast(®), Catafast(®), Cambia(®); hereafter referred to as diclofenac potassium powder) is a non-steroidal anti-inflammatory drug (NSAID), and is indicated for the acute treatment of migraine. This article reviews the pharmacological properties of diclofenac potassium ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-014-0186-y

    authors: Garnock-Jones KP

    更新日期:2014-08-01 00:00:00

  • Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation.

    abstract::Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11204710-000000000-00000

    authors: Keating GM,Lyseng-Williamson KA

    更新日期:2010-09-01 00:00:00

  • Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder.

    abstract::Aripiprazole (Abilify(®)) is an atypical antipsychotic that is widely used in the treatment of psychiatric conditions. Unlike other currently available atypical antipsychotics that primarily have varying degrees of dopamine D2 receptor antagonism, aripiprazole is a partial agonist at D2 and serotonin 5-HT1A receptors,...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0134-2

    authors: McKeage K

    更新日期:2014-02-01 00:00:00

  • A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.

    abstract:INTRODUCTION:The gabapentinoids pregabalin and gabapentin are being increasingly prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic dosages may present with low addictive liability levels, cases of misuse and rising numbers of related fatalities have been reported. OBJECTIV...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-016-0359-y

    authors: Chiappini S,Schifano F

    更新日期:2016-07-01 00:00:00

  • Pharmacological management of treatment-resistant obsessive-compulsive disorder.

    abstract::Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40-60% of patients with OCD. Management of the remaining 40-60% of patients wit...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11587860-000000000-00000

    authors: Abudy A,Juven-Wetzler A,Zohar J

    更新日期:2011-07-01 00:00:00

  • Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.

    abstract::The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucag...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0301-8

    authors: Calsolaro V,Edison P

    更新日期:2015-12-01 00:00:00

  • Antimicrobial Use in Patients with Dementia: Current Concerns and Future Recommendations.

    abstract::Infections are common in people with dementia, and antibiotic use is widespread, albeit highly variable, across healthcare settings and countries. The few studies conducted to date that consider the appropriateness of antibiotic prescribing specifically for people with dementia focus on people with advanced dementia a...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-017-0427-y

    authors: Parsons C,van der Steen JT

    更新日期:2017-06-01 00:00:00

  • Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.

    abstract::Cognitive dysfunction is a major cause of disability in patients with multiple sclerosis (MS). The prevalence of cognitive dysfunction is estimated at 45 to 65%. Natural history studies suggest that once cognitive dysfunction develops in a patient with MS, it is not likely to remit. Unlike physical disability in MS, c...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200216070-00002

    authors: Bagert B,Camplair P,Bourdette D

    更新日期:2002-01-01 00:00:00

  • The risk of stroke in patients with migraine and implications for migraine management.

    abstract::Assessing the risk of stroke in persons with migraine is complicated by the intricate relationship between these two conditions. Both migraine and stroke are common and co-morbidity may, in some cases, be coincidental. Given the overlap of clinical symptoms in stroke and migraine, each condition may also mimic the oth...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519080-00004

    authors: Tietjen GE

    更新日期:2005-01-01 00:00:00

  • Role of the melatonin system in the control of sleep: therapeutic implications.

    abstract::The circadian rhythm of pineal melatonin secretion, which is controlled by the suprachiasmatic nucleus (SCN), is reflective of mechanisms that are involved in the control of the sleep/wake cycle. Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT(1) (...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200721120-00004

    authors: Pandi-Perumal SR,Srinivasan V,Spence DW,Cardinali DP

    更新日期:2007-01-01 00:00:00

  • The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.

    abstract::How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological fac...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0288-1

    authors: Kingsberg SA,Clayton AH,Pfaus JG

    更新日期:2015-11-01 00:00:00

  • Correction to: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.

    abstract::NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...

    journal_title:CNS drugs

    pub_type: 已发布勘误

    doi:10.1007/s40263-018-0595-4

    authors: Papadopoulos D,Mitsikostas DD

    更新日期:2019-01-01 00:00:00

  • Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.

    abstract:BACKGROUND:Although levodopa is considered the most effective pharmacotherapy for motor symptoms of Parkinson's disease (PD), chronic use is associated with motor complications, including fluctuating response and unpredictable, involuntary movements called dyskinesia. ADS-5102 (amantadine) extended-release (ER) capsule...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-018-0498-4

    authors: Elmer LW,Juncos JL,Singer C,Truong DD,Criswell SR,Parashos S,Felt L,Johnson R,Patni R

    更新日期:2018-04-01 00:00:00

  • Does pharmacological treatment of ADHD in adults enhance parenting performance? Results of a double-blind randomized trial.

    abstract:OBJECTIVE:This study examines the effects of parental lisdexamfetamine (LDX) treatment on parent-child interactions. METHODS:Participants were 30 parents (27% were male) and their children aged 5-12 years, both diagnosed with DSM-IV attention-deficit/hyperactivity disorder (ADHD). Optimal LDX dose (30, 50, or 70 mg/da...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-014-0165-3

    authors: Waxmonsky JG,Waschbusch DA,Babinski DE,Humphrey HH,Alfonso A,Crum KI,Bernstein M,Slavec J,Augustus JN,Pelham WE

    更新日期:2014-07-01 00:00:00

  • Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

    abstract::Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdraw...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317070-00004

    authors: Hesse LM,von Moltke LL,Greenblatt DJ

    更新日期:2003-01-01 00:00:00

  • Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action.

    abstract::The aim of this review is to provide clinicians with a picture of the mechanisms by which: histamine and histaminergic agonists act on the vestibular system both peripherally and centrally; and histaminergic agonists and antagonists interfere with the recovery process after peripheral vestibular lesion. We have focuse...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115110-00004

    authors: Lacour M,Sterkers O

    更新日期:2001-01-01 00:00:00

  • Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?

    abstract::As in all patient populations, epilepsy is common in pregnant women. Consequently, approximately 1 in 200 pregnancies is exposed to antiepileptic drugs (AEDs). Although exposure to AEDs in utero has been associated with an increased risk of major fetal malformations, most women with epilepsy require medication through...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620100-00001

    authors: Adab N

    更新日期:2006-01-01 00:00:00

  • Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database.

    abstract:BACKGROUND:Responses to atomoxetine vary for individual patients with attention-deficit/hyperactivity disorder (ADHD). However, we do not know whether any factors can be used to reliably predict how individuals with ADHD will respond to treatment. OBJECTIVE:Our objective was to evaluate background variables that facil...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章

    doi:10.1007/s40263-016-0323-x

    authors: Bushe C,Sobanski E,Coghill D,Berggren L,De Bruyckere K,Leppämäki S

    更新日期:2016-04-01 00:00:00